BioTechne Corp (TECH)
(Delayed Data from NSDQ)
$73.99 USD
-0.53 (-0.71%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $73.99 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.99 USD
-0.53 (-0.71%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $73.99 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Zacks News
Immunomedics to be Acquired by Gilead for About 21 Billion
by Zacks Equity Research
Immunomedics Inc. (IMMU) will be acquired by Gilead (GILD) for about $21 billion.
Bayer Collaborates With Recursion for Fibrotic Diseases
by Zacks Equity Research
Bayer (BAYRY) inks deal with Recursion Pharmaceuticals for the treatment of fibrotic diseases.
Catalyst (CPRX) Eyes Firdapse Label Expansion Amid Competition
by Zacks Equity Research
Catalyst's (CPRX) efforts to expand Firdapse label are encouraging. However, with only a few candidates in the pipeline, the company's dependence on Firdapse for growth remains a matter of concern.
Gilead Submits sBLA to FDA for CAR-T in Non-Hodgkin Lymphomas
by Zacks Equity Research
Gilead submits a supplemental Biologics License Application to the FDA for Yescarta for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma.
Horizon Therapeutics' Stock Rises YTD on Approvals & Buyouts
by Zacks Equity Research
Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza, going forward in 2020. It is making efforts to expand the label for its marketed drugs.
Sesen Bio (SESN) Looks Good: Stock Adds 6.2% in Session
by Zacks Equity Research
Sesen Bio (SESN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Alexion (ALXN) Catches Eye: Stock Jumps 6.8%
by Zacks Equity Research
Alexion (ALXN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Reasons to Invest in Dr. Reddy's (RDY) Amid Coronavirus Woes
by Zacks Equity Research
Dr. Reddy's (RDY) continues to make products launches despite tepid sales volumes due to the COVID-19 pandemic.
5 Reasons to Invest in Horizon Therapeutics Amid Coronavirus
by Zacks Equity Research
Horizon Therapeutics (HZNP) expects continued strong growth for Krystexxa and Tepezza, going forward in 2020. The company's efforts to develop its pipeline are impressive.
Syros (SYRS) in Focus: Stock Moves 7.9% Higher
by Zacks Equity Research
Syros (SYRS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Agenus (AGEN) in Focus: Stock Moves 7.6% Higher
by Zacks Equity Research
Agenus (AGEN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Intercept (ICPT) Catches Eye: Stock Jumps 8.4%
by Zacks Equity Research
Intercept (ICPT) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Earnings Preview: Techne (TECH) Q4 Earnings Expected to Decline
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Techne (TECH) a Solid Growth Stock? 3 Reasons to Think " Yes "
by Zacks Equity Research
Techne (TECH) could produce exceptional returns because of its solid growth attributes.
REGN vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
REGN vs. TECH: Which Stock Is the Better Value Option?
LGND or TECH: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
LGND vs. TECH: Which Stock Is the Better Value Option?
LGND vs. TECH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LGND vs. TECH: Which Stock Is the Better Value Option?
Techne (TECH) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 23.01% and 5.31%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Techne (TECH) Q3 Earnings Expected to Decline
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REGN vs. TECH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
REGN vs. TECH: Which Stock Is the Better Value Option?
Techne (TECH) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of -5.26% and -3.50%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GILD vs. TECH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
GILD vs. TECH: Which Stock Is the Better Value Option?
CELG vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
CELG vs. TECH: Which Stock Is the Better Value Option?
Techne (TECH) Q1 Earnings Lag Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of -0.93% and 1.77%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?